630 related articles for article (PubMed ID: 15266474)
41. Modeling the cost effectiveness of secondary febrile neutropenia prophylaxis during standard-dose chemotherapy.
Timmer-Bonte JN; Adang EM; Termeer E; Severens JL; Tjan-Heijnen VC
J Clin Oncol; 2008 Jan; 26(2):290-6. PubMed ID: 18182670
[TBL] [Abstract][Full Text] [Related]
42. Recombinant granulocyte-macrophage colony-stimulating factor (rGM-CSF): an appraisal of its pharmacoeconomic status in neutropenia associated with chemotherapy and autologous bone marrow transplant.
Goa KL; Bryson HM
Pharmacoeconomics; 1994 Jan; 5(1):56-77. PubMed ID: 10146867
[TBL] [Abstract][Full Text] [Related]
43. Colony-stimulating factors in the prevention of solid tumors induced by chemotherapy in patients with febrile neutropenia.
Freyer G; Ligneau B; Trillet-Lenoir V
Int J Antimicrob Agents; 1998 Apr; 10(1):3-9. PubMed ID: 9624538
[TBL] [Abstract][Full Text] [Related]
44. Neutropenia-associated outcomes in adults with acute myeloid leukemia receiving cytarabine consolidation chemotherapy with or without granulocyte colony-stimulating factor.
Bradley AM; Deal AM; Buie LW; van Deventer H
Pharmacotherapy; 2012 Dec; 32(12):1070-7. PubMed ID: 23208834
[TBL] [Abstract][Full Text] [Related]
45. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer.
Crawford J; Ozer H; Stoller R; Johnson D; Lyman G; Tabbara I; Kris M; Grous J; Picozzi V; Rausch G
N Engl J Med; 1991 Jul; 325(3):164-70. PubMed ID: 1711156
[TBL] [Abstract][Full Text] [Related]
46. Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now?
Aapro M; Crawford J; Kamioner D
Support Care Cancer; 2010 May; 18(5):529-41. PubMed ID: 20191292
[TBL] [Abstract][Full Text] [Related]
47. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study.
Timmer-Bonte JN; de Boo TM; Smit HJ; Biesma B; Wilschut FA; Cheragwandi SA; Termeer A; Hensing CA; Akkermans J; Adang EM; Bootsma GP; Tjan-Heijnen VC
J Clin Oncol; 2005 Nov; 23(31):7974-84. PubMed ID: 16258098
[TBL] [Abstract][Full Text] [Related]
48. Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study.
Tan H; Tomic K; Hurley D; Daniel G; Barron R; Malin J
Curr Med Res Opin; 2011 Jan; 27(1):79-86. PubMed ID: 21091127
[TBL] [Abstract][Full Text] [Related]
49. Comparative effects of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor after high-dose cyclophosphamide cancer therapy.
Bregni M; Siena S; Di Nicola M; Dodero A; Peccatori F; Ravagnani F; Danesini G; Laffranchi A; Bonadonna G; Gianni AM
J Clin Oncol; 1996 Feb; 14(2):628-35. PubMed ID: 8636780
[TBL] [Abstract][Full Text] [Related]
50. Granulocyte colony stimulating factor (G-CSF) as an adjunct to antibiotics in the treatment of pneumonia in adults.
Cheng AC; Stephens DP; Currie BJ
Cochrane Database Syst Rev; 2003; (4):CD004400. PubMed ID: 14584011
[TBL] [Abstract][Full Text] [Related]
51. Meta-analysis: effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection.
Sung L; Nathan PC; Alibhai SM; Tomlinson GA; Beyene J
Ann Intern Med; 2007 Sep; 147(6):400-11. PubMed ID: 17876022
[TBL] [Abstract][Full Text] [Related]
52. Pharmacoeconomics of granulocyte colony-stimulating factor: a critical review.
Barnes G; Pathak A; Schwartzberg L
Adv Ther; 2014 Jul; 31(7):683-95. PubMed ID: 24989316
[TBL] [Abstract][Full Text] [Related]
53. Granulocyte-macrophage colony-stimulating factor support in therapy of high-risk acute lymphoblastic leukemia in children.
Saarinen-Pihkala UM; Lanning M; Perkkiö M; Mäkipernaa A; Salmi TT; Hovi L; Vettenranta K
Med Pediatr Oncol; 2000 May; 34(5):319-27. PubMed ID: 10797353
[TBL] [Abstract][Full Text] [Related]
54. [G-CSF in oncology].
Viret F; Gonçalves A; Tarpin C; Chabannon C; Viens P
Bull Cancer; 2006 May; 93(5):463-71. PubMed ID: 16777624
[TBL] [Abstract][Full Text] [Related]
55. A prospective randomised evaluation of G-CSF or G-CSF plus oral antibiotics in chemotherapy-treated patients at high risk of developing febrile neutropenia.
Lalami Y; Paesmans M; Aoun M; Munoz-Bermeo R; Reuss K; Cherifi S; Alexopoulos CG; Klastersky J
Support Care Cancer; 2004 Oct; 12(10):725-30. PubMed ID: 15235901
[TBL] [Abstract][Full Text] [Related]
56. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours.
Aapro MS; Cameron DA; Pettengell R; Bohlius J; Crawford J; Ellis M; Kearney N; Lyman GH; Tjan-Heijnen VC; Walewski J; Weber DC; Zielinski C;
Eur J Cancer; 2006 Oct; 42(15):2433-53. PubMed ID: 16750358
[TBL] [Abstract][Full Text] [Related]
57. Granulocyte-colony stimulating factor for the prevention of chemotherapy-induced febrile neutropenia in the adult cancer patient population of Southern Israel.
Gilad J; Riesenberg K; Mermershtain W; Borer A; Porath A; Schlaeffer F
Support Care Cancer; 1999 Jul; 7(4):260-4. PubMed ID: 10423052
[TBL] [Abstract][Full Text] [Related]
58. The role of myelopoietic growth factors in managing cancer in the elderly.
Balducci L; Carreca I
Drugs; 2002; 62 Suppl 1():47-63. PubMed ID: 12479594
[TBL] [Abstract][Full Text] [Related]
59. Myeloid growth factors as anti-infective measures in children with leukemia and lymphoma.
Lehrnbecher T; Creutzig U
Expert Rev Hematol; 2009 Apr; 2(2):159-72. PubMed ID: 21083449
[TBL] [Abstract][Full Text] [Related]
60. Granulocyte-macrophage-colony stimulating factor for prevention of neutropenia and infections in children and adolescents with solid tumors. Results of a prospective randomized study.
Burdach SE; Müschenich M; Josephs W; Frisch J; Schulz G; Jürgens H; Göbel U
Cancer; 1995 Aug; 76(3):510-6. PubMed ID: 8625134
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
